Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discusses phase III trial results showing that in newly diagnosed metastatic stage IV breast cancer, locoregional treatment of the primary tumor did not offer a greater survival benefit than systemic therapy (Abstract LBA2).
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance and new format.
Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2-mutated metastatic non–small cell lung cancer. The data show clinical activity with high overall response rates and durable responses (Abstract 9504).
Christopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional benefit of swallow-sparing intensity-modulated radiotherapy in oro- and hypopharyngeal cancers (Abstract 6508).
Sarah A. Holstein, MD, PhD, of the University of Nebraska Medical Center, discusses top myeloma abstracts from the ASCO20 Virtual Scientific Program: the ENDURANCE trial on carfilzomib, lenalidomide, dexamethasone, and bortezomib; the STaMINA study on transplantation strategies; a first-in-human study on the novel CELMoD agent CC-92480 plus dexamethasone; the CARTITUDE-1 trial on CAR T-cell therapy; and a phase I study of teclistamab (Abstracts LBA3, 8506, 8500, 8505, and 100).
David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castleman, a disease of the lymph nodes, his multiple near-death experiences, and the path that led him to develop a cooperative research effort making a difference for him and other patients with this idiopathic orphan illness.
